Short Sellers Grow More Selective on Major Pharma Stocks
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The September 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in patients with established cardiovascular disease and elevated levels of lipoprotein(a).
Clinical-stage biopharmaceutical company Kodiak Sciences expects to price 9 million shares for an initial public company valued up to more than $155 million.
There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large…
Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut. They all make good sense now, and all have outstanding upside potential.
Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were very positive.
Changing U.S. demographics will change the proportion of Americans who suffer from Alzheimer's and other dementia-related diseases. The diseases are forecast to hit Hispanics and African Americans hardest.
Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson’s disease psychosis.
Friday's trading session showed Novavax on the leaderboard after an analyst upgrade from JPMorgan.
GTx shares were absolutely crushed on Friday after the company announced results from its mid-stage trial in post-menopausal women with stress urinary incontinence.
A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove to be huge.
Eli Lilly spin-off Elanco Animal Health made a strong entrance to the market on Thursday.
Adverum Biotechnologies shares made a handy gain on Thursday after the company announced a key update from the FDA.
AbbVie shares took a dip on Wednesday after it was announced that the pharma giant would be facing a lawsuit from the California Department of Insurance in regards to allegedy kickbacks given to health…